Granules India share news, announcements and annual reports
NSE: GRANULESBSE: 532482Pharmaceuticals & BiotechnologySmall Cap
Granules India Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2002 on BSE, Jun 2005 on NSE
Last close ₹839.75up ₹2.40 (0.29%)BSE ₹839.55
Share price at the NSE close on 30 Oct 2026. Previous close ₹837.35.
30 Oct: open ₹839.40, high ₹859.70, low ₹837.00
52-week range of traded prices to 30 Oct 2026
₹529.85Low, 25 Nov 2025₹923.65High, 15 Sep 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹22,907 Cr403rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 34.58
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.21%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.26
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 7,78,58145.0% delivered
Granules India orders, deals and press releases
209 filed, newest first. Page 5 of 5.
May 2007
14 May · Business
Press release on receipt of approvals from US FDA for the facilities of the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 May · Business
May 08, 2007 that "The International Finance Corporation (IFC) has agreed to subscribe upto 22,00,000 equity shares of the Company of the face value of Rs.10/- each (which will be 11.48% of the post issue capital) subject to the approval of Board of Directors and Shareholders of the Company".9 May · Business
"The Board of Directors of the Company at their meeting held today (i.e. May 09, 2007) had considered and approved issue of 22,00,000 equity shares of Rs.10/- each fully paid-up at Rs.118.10 per share (including premium) to International Finance Corporation (IFC) on preferential basis, subject to the approval of the shareholders of the Company". Further the Company has submitted to the Exchange a copy of the press release dated May 09, 2007, titled "Granules India invites shareholders approval for IFC investment". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2007
30 Apr · Business
Press release dated April 30, 2007, titled "Granules India posts 24.8% growth in Q3 FY07". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Apr · Business
Board of Directors of the company at their meeting held today (i.e. April 03, 2007) had considered and approved issue of 22,11,200 equity shares of Rs.10/- each fully paid-up at Rs. 105.50 per share (including premium) to ISP Investco LLC., on preferential basis, subject to the approval of the shareholders of the Company.
Mar 2007
6 Mar · Business
Granules India Limited had informed the Exchange regarding Setting up of a Joint Venture in China . The Company has informed the Exchange that the Agreement entered between Granules India Limited and Hubei Biocause Heilen Pharmaceutical Company Limited, China for setting up of a Joint Venture Company in China has been approved by the Government of China. The Joint Venture Company in the name of Hubei Granules Biocause Pharmaceutical Co. Ltd., has been registered and will now become operational. The JV company will manufacture Ibuprofen API presently.5 Mar · Business
Press release dated March 05, 2007 on 'Matchland Pty Ltd, (trading as New Products Development) and Granules India Limited signing an Outsourcing Agreement'. The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2007
19 Jan · Business
Press release dated January 19, 2007, titled "Granules India posts 37% growth in Net Profit in Q2 FY07". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jan · Business
Press release dated January 17, 2007 which is as follows: "Granules India is pleased to announce the signing of a Master Service Agreement with GlaxoSmithKline Consumer Healthcare R&D (GSK CH R&D). This agreement is the first step in this new relationship that will involve Granules undertaking product development projects".